kabutan

BrightPath Biotherapeutics, Apr-Dec (Cumulative 3Q) Net Income Loss Widens, Oct-Dec Net Income Loss Widens

Fri Feb 13, 2026 3:32 pm JST Earnings

4594 BrightPath Biotherapeutics Co., Ltd. 【J-GAAP】

Earnings Report

BrightPath Biotherapeutics Co., Ltd. <4594> [TSE Growth] announced its financial results after the market closed on February 13th (15:32). The net loss (non-consolidated) for the cumulative third quarter of the fiscal year ending March 2026 (April to December) expanded to a loss of 955 million yen (compared to a loss of 815 million yen in the same period last year).

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the net loss for the January to March period (4Q) is expected to further decrease loss of 211 million yen (compared to a loss of 336 million yen in the same period last year).

In the most recent three-month period, from October to December (3Q), the net loss expanded to loss of 493 million yen (compared to a loss of 277 million yen in the same period last year).

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 0 -947 -947 -953 -15.1 ー Feb 9, 2024 J-GAAP
Apr - Dec, 2024 0 -815 -812 -815 -10.3 ー Feb 14, 2025 J-GAAP
Apr - Dec, 2025 0 -956 -952 -955 -9.1 ー Feb 13, 2026 J-GAAP
YoY － -17.3% -17.2% -17.2% +11.9%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 1 -618 -610 -613 -7.5 0 May 9, 2025 J-GAAP
Oct - Mar, 2025 Guidance 0 -718 -704 -704 -6.2 0 Nov 14, 2025 J-GAAP
YoY － -16.2% -15.4% -14.8% +17.2%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 0 -1,155 -1,158 -1,168 -18.2 0 May 10, 2024 J-GAAP
Mar, 2025 1 -1,160 -1,147 -1,151 -14.1 0 May 9, 2025 J-GAAP
Mar, 2026 Guidance 0 -1,182 -1,164 -1,166 -10.3 0 May 9, 2025 J-GAAP
YoY － -1.9% -1.5% -1.3% +26.9%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 0 -273 -275 -277 -3.5 -Inf Feb 14, 2025 J-GAAP
Jan - Mar, 2025 1 -345 -335 -336 -4.1 -34,500.0 May 9, 2025 J-GAAP
Apr - Jun, 2025 0 -245 -240 -241 -2.6 -Inf Aug 8, 2025 J-GAAP
Jul - Sep, 2025 0 -219 -220 -221 -2.2 -Inf Nov 14, 2025 J-GAAP
Oct - Dec, 2025 0 -492 -492 -493 -4.7 -Inf Feb 13, 2026 J-GAAP
YoY － -80.2% -78.9% -78.0% -33.7%

Related Articles